

Raji-Null Cells

Human lymphoblast-like cells

Catalog code: raji-null

<https://www.invivogen.com/raji-null>

For research use only

Version 21B12-ED

PRODUCT INFORMATION

Contents and Storage

- 3-7 x 10⁶ Raji-Null cells in a cryovial or shipping flask.

IMPORTANT: If cells provided in a cryovial are not frozen upon arrival, contact InvivoGen immediately.

- **1 ml of Blasticidin** (10 mg/ml). Store at 4°C or at -20°C.*
 - **1 ml of Normocin™** (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria and fungi. Store at -20°C.*
- *The expiry date is specified on the product label.

Note: Data sheets for all components are available on our website.

Handling Frozen Cells Upon Arrival

Cells must be thawed immediately upon receipt and grown according to handling procedures (as described on the next page) to ensure the best cell viability and proper assay performance.

Note: Avoid freezing cells upon receipt as it may result in irreversible damage to the cell line.

Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedures.

IMPORTANT: For cells that arrive in a shipping flask please refer to the enclosed 'cell recovery procedure'.

Cell Line Stability

Genetic instability is a biological phenomenon that occurs in all stably transfected cells. Cells will undergo genotypic changes resulting in reduced responsiveness over time in normal cell culture conditions. Therefore, it is critical to prepare an adequate number of frozen stocks at early passages. To ensure maximum efficiency, do not passage Raji-Null cells more than 20 times and maintain cells in growth medium supplemented with the selective antibiotic.

Quality Control

- Human CD20 expression has been verified by flow-cytometry.
- Induction of antibody-dependent cellular cytotoxicity (ADCC) has been validated using InvivoGen's anti-hCD20-hIgG1 antibody and Jurkat-NFAT Lucia™ CD16 reporter cell line.
- The stability for 20 passages following thawing has been verified.
- Raji-Null cells are guaranteed mycoplasma-free.

RESTRICTIONS

These cells are distributed for research purposes only.

This product is covered by a Limited Use License. By use of this product, the buyer agrees the terms and conditions of all applicable Limited Use Label Licenses. For non-research use, such as screening, quality control or clinical development, contact info@invivogen.com.


INTRODUCTION

Raji lymphoblast-like cells were established from a Burkitt's lymphoma patient. These cells have been successfully used as target cells in human effector studies such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells, Natural Killer cells, or Jurkat-derived reporter T cells. Indeed, Raji cells constitutively express different surface antigens, such as CD20, CD19 and PD-L1 (programmed cell death ligand 1), that can be targeted by specific antibodies (Abs). CD20 and CD19 are highly expressed by Raji cells, and these molecules have been targeted for Ab-mediated immunotherapies. Rituximab, ofatumumab, and obinutuzumab are FDA-approved anti-hCD20 monoclonal Abs (mAbs) to treat non-Hodgkin's B-cell lymphoma or chronic lymphocytic leukaemia¹. Blinatumomab is a bispecific Ab that binds hCD3 on T cells, and hCD19 on B cells. It induces proliferation and cytotoxic activity of the engaged T cells². PD-L1 is expressed at low levels by Raji-cells, probably due to their tumoral origin. It is a clinically-relevant target in Ab-mediated therapy for a wide range of cancers³.

1. **Almagro J.C. et al., 2018.** Progress and challenges in the development of antibodies for cancer therapy. *Front. Immunol.* 8:1751. 2. **Bargou R. et al., 2008.** Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. *Science.* 321(5891):974-7. 3. **Ribas A. and Wolchok J.D., 2018.** Cancer immunotherapy using checkpoint blockade. *Science.* 359:1350-55.

PRODUCT DESCRIPTION

Raji-Null cells were developed from the Raji cell line. They constitutively express the CD19, CD20 and PD-L1 antigens, and a resistance gene to Blasticidin. These cells can be used as target cells in ADCC assays using anti-human CD19, CD20 or PD-L1 mAbs, or as negative control target cells in ADCC assays targeting other molecules, such as human CTLA-4 or PD-1. Raji-Null cells may also be used in T-cell activation assays using anti-hCD19-CD3 bispecific Abs. Their resistance to blasticidin allows them to be used with the same selection pressure than other Raji-derived target cells from InvivoGen's collection (For more information, visit <https://www.invivogen.com/raji-derived-target-cells>).



Examples of applications using the Raji-Null cell line.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



Any questions about our cell lines?

Visit our FAQ page.

 **InvivoGen**
www.invivogen.com

SAFETY CONSIDERATIONS

Biosafety Level 2

Raji-Null cells were derived from Raji cells, which contain Herpesvirus (EBV), and thus may require Biosafety Level 2. The biosafety level varies by country. Please check with your country's regulatory authority regarding the use of these cells.

HANDLING PROCEDURES

Required Cell Culture Medium

- **Growth Medium:** IMDM, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated fetal bovine serum (FBS; 30 min at 56°C), Pen-Strep (100 U/ml-100 µg/ml), 100 µg/ml **Normocin™**
- **Freezing Medium:** 90% FBS, 10% DMSO
- **Test Medium:** IMDM, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated FBS, Pen-Strep (100 U/ml-100 µg/ml) **without Normocin and Blasticidin**

Required Selective Antibiotic

- **Blasticidin**

Initial Culture Procedure

The first propagation of cells should be for generating stocks for future use. This ensures the stability and performance of the cells for subsequent experiments.

1. Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing must be rapid.
2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol.
Note: All steps from this point should be carried out under strict aseptic conditions.
3. Transfer cells in a larger vial containing 15 ml of pre-warmed growth medium. **Do not add selective antibiotics until the cells have been passaged twice.**
4. Centrifuge cells at 150 x g (RCF) for 10 mins.
5. Remove supernatant containing the cryoprotective agent and resuspend cells with 1 ml of growth medium without selective antibiotics.
6. Transfer the vial contents to a T-25 culture flask containing 5 ml of growth medium.
7. Place the culture at 37°C in 5% CO₂.

Frozen Stock Preparation

1. Resuspend cells at a density of 5-7 x 10⁶ cells/ml in freezing medium freshly prepared with cold FBS.
2. Aliquot 1 ml cells into cryogenic vials.
3. Place vials in a freezing container and store at -80°C overnight.
4. Transfer vials to liquid nitrogen for long-term storage.

Note: If properly stored, cells should remain stable for years.

Cell Maintenance

1. After cells have recovered, subculture in growth medium with an initial seeding density of ~300,000 cells/ml. To maintain selection pressure, add 10 µg/ml of **Blasticidin** to the growth medium every other passage.
2. Renew growth medium twice a week.

Cell-Handling Recommendations

To ensure the best results:

- Use Raji-Null cells with less than 20 passages.
- Handling of cells should be as short as possible to prevent any damage resulting from the prolonged stay at room temperature without 5% CO₂.

APPLICATION

Raji-Null cells can be used as target cells in antibody-dependent cellular cytotoxicity (ADCC) reporter assays using InvivoGen's **Jurkat-Lucia™ NFAT-CD16 cells** and anti-human CD20 mAbs, or as negative control target cells in ADCC assays targeting other molecules. *For more information, visit <https://www.invivogen.com/jurkat-lucia-nfat-cd16-cells>.* Raji-Null cells may also be used in T-cell activation assays using anti-hCD19-CD3 bispecific Abs.

For more information, visit <https://www.invivogen.com/anti-hcd19-cd3>.

ADCC REPORTER ASSAYS

Cell Preparation

1. Centrifuge Raji-Null cells at 150 x g (RCF) for 10 mins or 300 x g (RCF) for 5 mins.
2. Remove supernatant and resuspend Raji-Null cells at 1.1 x 10⁶ cells/ml in fresh, pre-warmed test medium.
*Note: In steps 3 & 4, **Jurkat-Lucia™ NFAT-CD16 cells** should be prepared just prior to their addition to the antibody-coated target cells.*
3. Centrifuge **Jurkat-Lucia™ NFAT-CD16 cells** at 150 x g (RCF) for 10 mins or 300 x g (RCF) for 5 mins.
4. Remove supernatant and resuspend **Jurkat-Lucia™ NFAT-CD16 cells** at 2.2 x 10⁶ cells/ml in fresh, pre-warmed test medium.
Important: To ensure reproducible results, homogenize the cell suspensions.

ADCC Induction

Below is a protocol for end-point readings using a luminometer. This protocol can be adapted for use with kinetic measurements.

1. Add 20 µl of test mAb (targeting human CD20 or another antigen) per well including a positive control (e.g. **Anti-hCD20-hlgG1**) and a negative control (e.g. **Anti-β-Gal-hlgG1**).
Note: We recommend to prepare 1:4 or 1:2 dilution series.
2. Add 90 µl of Raji-Null cell suspension (~100,000 cells) per well of a flat-bottom 96-well plate.
3. Incubate the plate at 37°C in a CO₂ incubator for 1 h.
4. Add 90 µl of **Jurkat-Lucia™ NFAT-CD16 cell** suspension (~200,000 cells) per well.
5. Incubate the plate at 37°C in a CO₂ incubator for 6 h.
6. Prepare **QUANTI-Luc™** following the instructions on the data sheet.
7. Transfer 20 µl of co-incubated Raji-Null and **Jurkat-Lucia™ NFAT-CD16 cell** supernatant into a 96-well white (opaque) or black plate, or a luminometer tube.
8. Add 50 µl of **QUANTI-Luc™** per well.
9. Proceed **immediately** with the measurement.

RELATED PRODUCTS

Product	Description	Cat. Code
Anti-β-Gal-hlgG1	Control antibody	bgal-mab1
Anti-hCD19-CD3	Bispecific antibody	bimab-hcd19cd3
Anti-hCD20-hlgG1	Anti-hCD20 antibody	hcd20-mab1
Blasticidin	Selection antibiotic	ant-bl-05
Jurkat-Lucia™ NFAT-CD16 cells	ADCC reporter cell line	jknl-nfat-cd16
QUANTI-Luc™	Lucia detection medium	rep-qlc1
Raji-hCTLA4 cells	ADCC target cell line	raji-hCTLA4
Raji-hPD-1 cells	ADCC target cell line	raji-hpd1
Raji-hPD-L1 cells	ADCC target cell line	raji-hpd1l

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



Any questions about our cell lines?

Visit our FAQ page.

 **InvivoGen**
www.invivogen.com